Comparative Pharmacology
Head-to-head clinical analysis: BLOCADREN versus TIMOPTIC XE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLOCADREN versus TIMOPTIC XE.
BLOCADREN vs TIMOPTIC-XE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective beta-adrenergic receptor antagonist; blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
Timolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 adrenergic receptors. In the eye, it reduces aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium, thereby lowering intraocular pressure.
Hypertension: initial 10 mg PO twice daily, increase gradually to 20-40 mg/day; maximum 60 mg/day. Post-MI: 10 mg PO twice daily starting 1-4 weeks post-infarction.
Instill one drop of 0.25% or 0.5% solution in the affected eye(s) once daily in the morning.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; prolonged in renal impairment (up to 24 hours) and elderly; dose adjustment required in CrCl <35 mL/min
Plasma: 4-6 hours; prolonged in renal impairment. Systemic half-life after ocular dosing: 4-5 hours.
Primarily renal (80-95% unchanged), minor hepatic metabolism to inactive metabolites, minimal fecal excretion (<5%)
Renal: 20% unchanged; remainder as metabolites via urine. Minor biliary/fecal elimination.
Category C
Category C
Ophthalmic Beta Blocker
Ophthalmic Beta Blocker